Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa‐2a plus ribavirin

Summary Background The impact of reduced drug exposure on outcomes in patients with chronic hepatitis C has not been determined in routine clinical practice. Aim To examine the impact of exposure to peginterferon alfa‐2a and ribavirin on early virological response (EVR) and sustained virological r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alimentary pharmacology & therapeutics 2008-07, Vol.28 (1), p.43-50
Hauptverfasser:	BAIN, V. G., LEE, S. S., PELTEKIAN, K., YOSHIDA, E. M., DESCHÊNES, M., SHERMAN, M., BAILEY, R., WITT‐SULLIVAN, H., BALSHAW, R., KRAJDEN, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Digestive system Gastroenterology. Liver. Pancreas. Abdomen Hepatitis C virus Human viral diseases Infectious diseases Medical sciences Pharmacology. Drug treatments Viral diseases Viral hepatitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Background The impact of reduced drug exposure on outcomes in patients with chronic hepatitis C has not been determined in routine clinical practice. Aim To examine the impact of exposure to peginterferon alfa‐2a and ribavirin on early virological response (EVR) and sustained virological response (SVR) in treatment‐naïve patients with HCV genotype 1 infection enrolled in a large expanded access programme. Methods Eight hundred and ninety‐one patients treated for 48 weeks with an initial ribavirin dose of 800 or 1000/1200 mg/day were evaluated. Ribavirin 1000 mg/day (
ISSN:	0269-2813 1365-2036
DOI:	10.1111/j.1365-2036.2008.03705.x